Rigel Pharmaceuticals, Inc./$RIGL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Ticker
$RIGL
Sector
Primary listing
Employees
163
Headquarters
Website
RIGL Metrics
BasicAdvanced
$687M
6.11
$6.20
1.16
-
Price and volume
Market cap
$687M
Beta
1.16
52-week high
$43.72
52-week low
$15.50
Average daily volume
573K
Financial strength
Total debt to equity
74.504
Interest coverage (TTM)
15.70%
Profitability
EBITDA (TTM)
121.376
Gross margin (TTM)
84.81%
Net profit margin (TTM)
40.17%
Operating margin (TTM)
42.17%
Effective tax rate (TTM)
0.91%
Revenue per employee (TTM)
$1,730,000
Management effectiveness
Valuation
Price to earnings (TTM)
6.108
Price to revenue (TTM)
2.395
Price to book
8.29
Price to tangible book (TTM)
12.12
Growth
Revenue change (TTM)
79.13%
Earnings per share change (TTM)
2,698.26%
3-year revenue growth (CAGR)
48.65%
10-year revenue growth (CAGR)
25.72%
3-year earnings per share growth (CAGR)
8.60%
10-year earnings per share growth (CAGR)
-1.11%
Bulls say / Bears say
Net product sales for Q2 2025 grew 76% YoY to $58.9 million, supporting management’s decision to raise full-year net product sales guidance to $210–220 million. (PRNewswire)
Rigel completed enrollment in the dose escalation part of its Phase 1b study of R289 for relapsed or refractory lower-risk MDS, advancing its clinical pipeline on schedule. (PRNewswire)
Cash, cash equivalents and short-term investments rose to $108.4 million as of June 30, 2025, up from $77.3 million at year-end 2024, strengthening the company’s runway for ongoing R&D programs. (Investing.com)
Q2 2025 included a one-off $40 million non-cash contract revenue from the release of Lilly cost-share liability, which is unlikely to recur and may overstate ongoing profitability. (Investing.com)
Total costs and expenses rose 11.5% YoY to $40.6 million in Q2 2025, driven by higher product costs, expanded R&D activities and increased personnel expenses, which could pressure future margins. (Investing.com)
Rigel notified Lilly in April 2025 that it would not exercise its opt-in for ocadusertib in non-CNS indications, limiting its participation to milestone and royalty streams and foregoing potential co-development upside. (PRNewswire)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
RIGL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rigel Pharmaceuticals, Inc. stock?
Rigel Pharmaceuticals, Inc. (RIGL) has a market cap of $687M as of November 06, 2025.
What is the P/E ratio for Rigel Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Rigel Pharmaceuticals, Inc. (RIGL) stock is 6.11 as of November 06, 2025.
Does Rigel Pharmaceuticals, Inc. stock pay dividends?
No, Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Rigel Pharmaceuticals, Inc. dividend payment date?
Rigel Pharmaceuticals, Inc. (RIGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Rigel Pharmaceuticals, Inc.?
Rigel Pharmaceuticals, Inc. (RIGL) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.